Safety, Tolerability, and PK of Single Subcutaneous Dose of GSK4771261 in Healthy Participants

Phase 1, randomised, double-blind trial in Kidney disease comparing GSK4771261 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events, Injection Site Reactions, and Serious Adverse Events at 13 weeks, Number of Participants with Clinically Significant Changes from Baseline in Vital Signs at 13 weeks and 5 more. Started May 2026; status: recruiting.